Merck pens $300M-per-product collab with Epitopea to locate 'hidden' tumor antigens
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret antigens that could form the backbone of off-the-shelf immunotherapies.
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret antigens that could form the backbone of off-the-shelf immunotherapies.
